239 related articles for article (PubMed ID: 23173554)
1. Preclinical evaluation of Gd-DTPA and gadomelitol as contrast agents in DCE-MRI of cervical carcinoma interstitial fluid pressure.
Hompland T; Ellingsen C; Rofstad EK
BMC Cancer; 2012 Nov; 12():544. PubMed ID: 23173554
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the interstitial fluid pressure of tumors by dynamic contrast-enhanced magnetic resonance imaging with contrast agents of different molecular weights.
Hompland T; Gulliksrud K; Ellingsen C; Rofstad EK
Acta Oncol; 2013 Apr; 52(3):627-35. PubMed ID: 23126523
[TBL] [Abstract][Full Text] [Related]
3. Connective tissue of cervical carcinoma xenografts: associations with tumor hypoxia and interstitial fluid pressure and its assessment by DCE-MRI and DW-MRI.
Hompland T; Ellingsen C; Galappathi K; Rofstad EK
Acta Oncol; 2014 Jan; 53(1):6-15. PubMed ID: 23445339
[TBL] [Abstract][Full Text] [Related]
4. Interstitial fluid pressure and associated lymph node metastasis revealed in tumors by dynamic contrast-enhanced MRI.
Hompland T; Ellingsen C; Øvrebø KM; Rofstad EK
Cancer Res; 2012 Oct; 72(19):4899-908. PubMed ID: 23027087
[TBL] [Abstract][Full Text] [Related]
5. DCE-MRI of patient-derived xenograft models of uterine cervix carcinoma: associations with parameters of the tumor microenvironment.
Hauge A; Wegner CS; Gaustad JV; Simonsen TG; Andersen LMK; Rofstad EK
J Transl Med; 2017 Nov; 15(1):225. PubMed ID: 29100521
[TBL] [Abstract][Full Text] [Related]
6. Assessment of tumor hypoxia and interstitial fluid pressure by gadomelitol-based dynamic contrast-enhanced magnetic resonance imaging.
Gulliksrud K; Hompland T; Galappathi K; Rofstad EK
Radiother Oncol; 2011 Oct; 101(1):217-22. PubMed ID: 21840612
[TBL] [Abstract][Full Text] [Related]
7. Dynamic contrast-enhanced magnetic resonance imaging of tumor interstitial fluid pressure.
Gulliksrud K; Brurberg KG; Rofstad EK
Radiother Oncol; 2009 Apr; 91(1):107-13. PubMed ID: 18973959
[TBL] [Abstract][Full Text] [Related]
8. Dynamic contrast-enhanced magnetic resonance imaging of the metastatic potential of tumors: a preclinical study of cervical carcinoma and melanoma xenografts.
Øvrebø KM; Ellingsen C; Hompland T; Rofstad EK
Acta Oncol; 2013 Apr; 52(3):604-11. PubMed ID: 22671573
[TBL] [Abstract][Full Text] [Related]
9. DCE-MRI of the hypoxic fraction, radioresponsiveness, and metastatic propensity of cervical carcinoma xenografts.
Ellingsen C; Hompland T; Galappathi K; Mathiesen B; Rofstad EK
Radiother Oncol; 2014 Feb; 110(2):335-41. PubMed ID: 24231244
[TBL] [Abstract][Full Text] [Related]
10. Dynamic contrast-enhanced MRI of the microenvironment of pancreatic adenocarcinoma xenografts.
Wegner CS; Hauge A; Gaustad JV; Andersen LMK; Simonsen TG; Galappathi K; Rofstad EK
Acta Oncol; 2017 Dec; 56(12):1754-1762. PubMed ID: 28661213
[TBL] [Abstract][Full Text] [Related]
11. Assessment of hypoxia in human cervical carcinoma xenografts by dynamic contrast-enhanced magnetic resonance imaging.
Ellingsen C; Egeland TA; Gulliksrud K; Gaustad JV; Mathiesen B; Rofstad EK
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):838-45. PubMed ID: 19215820
[TBL] [Abstract][Full Text] [Related]
12. Dynamic contrast-enhanced magnetic resonance imaging of tumors: preclinical validation of parametric images.
Egeland TA; Simonsen TG; Gaustad JV; Gulliksrud K; Ellingsen C; Rofstad EK
Radiat Res; 2009 Sep; 172(3):339-47. PubMed ID: 19708783
[TBL] [Abstract][Full Text] [Related]
13. Dynamic contrast-enhanced magnetic resonance imaging of the metastatic potential of melanoma xenografts.
Ovrebø KM; Ellingsen C; Galappathi K; Rofstad EK
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):e121-7. PubMed ID: 22381901
[TBL] [Abstract][Full Text] [Related]
14. Assessment of tumor radioresponsiveness and metastatic potential by dynamic contrast-enhanced magnetic resonance imaging.
Øvrebø KM; Gulliksrud K; Mathiesen B; Rofstad EK
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):255-61. PubMed ID: 21816291
[TBL] [Abstract][Full Text] [Related]
15. Intraindividual in vivo comparison of gadolinium contrast agents for pharmacokinetic analysis using dynamic contrast enhanced magnetic resonance imaging.
Liang J; Sammet S; Yang X; Jia G; Takayama Y; Knopp MV
Invest Radiol; 2010 May; 45(5):233-44. PubMed ID: 20351653
[TBL] [Abstract][Full Text] [Related]
16. Peritumoral interstitial fluid flow velocity predicts survival in cervical carcinoma.
Hompland T; Lund KV; Ellingsen C; Kristensen GB; Rofstad EK
Radiother Oncol; 2014 Oct; 113(1):132-8. PubMed ID: 25443501
[TBL] [Abstract][Full Text] [Related]
17. Correlations between dynamic contrast-enhanced magnetic resonance imaging-derived measures of tumor microvasculature and interstitial fluid pressure in patients with cervical cancer.
Haider MA; Sitartchouk I; Roberts TP; Fyles A; Hashmi AT; Milosevic M
J Magn Reson Imaging; 2007 Jan; 25(1):153-9. PubMed ID: 17173303
[TBL] [Abstract][Full Text] [Related]
18. DCE-MRI of locally-advanced carcinoma of the uterine cervix: Tofts analysis versus non-model-based analyses.
Lund KV; Simonsen TG; Kristensen GB; Rofstad EK
Radiat Oncol; 2020 Apr; 15(1):79. PubMed ID: 32293487
[TBL] [Abstract][Full Text] [Related]
19. Dynamic contrast-enhanced magnetic resonance imaging of human cervical carcinoma xenografts: pharmacokinetic analysis and correlation to tumor histomorphology.
Ellingsen C; Egeland TA; Galappathi K; Rofstad EK
Radiother Oncol; 2010 Nov; 97(2):217-24. PubMed ID: 20656365
[TBL] [Abstract][Full Text] [Related]
20. Comparison of single- and dual-tracer pharmacokinetic modeling of dynamic contrast-enhanced MRI data using low, medium, and high molecular weight contrast agents.
Orth RC; Bankson J; Price R; Jackson EF
Magn Reson Med; 2007 Oct; 58(4):705-16. PubMed ID: 17899608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]